Vitality Watch

Dossier rss preclinical 03-oct-2026
Animal model, organoid, or cell-culture result — not yet human

Elamipretide Rejuvenates Oocyte Quality and Restores Female Fertility During Reproductive Aging

Key claim: Elamipretide rejuvenates oocyte quality and restores female fertility during reproductive aging.

Abstract

Aging Cell, Volume 25, Issue 10, October 2026.

Why this matters

Elamipretide (SS-31) is already in human trials for mitochondrial myopathy and age-related cardiac and visual phenotypes; extending it into oocyte quality adds the female germline to the list of tissues where a cardiolipin-binding peptide reportedly rescues age-related mitochondrial failure. The finding is preclinical, and the pitch of ‘restoring fertility’ is substantially ahead of any human reproductive-aging readout — the mechanism→intervention gap is the central caveat.

Source

Link

Briefing card

Elamipretide Rejuvenates Oocyte Quality and Restores Female Fertility During Reproductive Aging
Stage: preclinical · rss · 03-oct-2026

If you follow elamipretide or ovarian-aging research, this adds a preclinical fertility-restoration result in animals — not a human fertility outcome.

Elamipretide rejuvenates oocyte quality and restores female fertility during reproductive aging.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: url:https://onlinelibrary.wiley.com/doi/10.1111/acel.70749?af=R

build build 880 · 2bcef25 · 2026-11-18